Attached files

file filename
10-Q - FORM 10-Q - GALECTIN THERAPEUTICS INCd402747d10q.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR33.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A) - GALECTIN THERAPEUTICS INCd402747dex312.htm
EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - GALECTIN THERAPEUTICS INCd402747dex321.htm
EX-10.3 - EMPLOYMENT AGREEMENT - GALECTIN THERAPEUTICS INCd402747dex103.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A) - GALECTIN THERAPEUTICS INCd402747dex311.htm
EXCEL - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR6.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR9.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR2.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR5.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR3.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR1.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR7.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR8.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR4.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR21.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR14.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR17.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR23.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR29.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR32.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR26.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR30.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR10.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR24.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR20.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR15.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR28.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR13.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR16.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR19.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR27.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR12.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR11.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR25.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR31.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR22.htm
EX-32.2 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - GALECTIN THERAPEUTICS INCd402747dex322.htm
v2.4.0.6
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2012
Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants

Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:

 

     Three Months
Ended
September 30,
     Nine Months
Ended
September 30,
 
     2012      2011      2012      2011  
     (in thousands)  

Research and development

   $ 248       $ 270       $ 756       $ 1,407   

General and administrative

     571         379         1,414         1,281   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total stock-based compensation expense

   $ 819       $ 649       $ 2,170       $ 2,688   
  

 

 

    

 

 

    

 

 

    

 

 

 
Summary of Stock Option Activity

The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2011 through September 30, 2012:

 

     Shares     Weighted
Average
Exercise
Price
 

Outstanding, December 31, 2011

     3,091,474      $ 6.83   

Granted

     730,000        2.16   

Exercised

     (51,830     2.31   

Options forfeited/cancelled

     (228,014     7.65   
  

 

 

   

Outstanding, September 30, 2012

     3,541,630      $ 5.88   
  

 

 

   
Weighted Average Assumptions Used to Determine Fair Value of Options Granted

The following weighted average assumptions were used:

 

     Nine Months Ended
September 30,
    Cumulative
Period from
Inception
(July 10,
2000) to
September 30,
 
     2012     2011     2012  

Risk-free interest rate

     0.84     1.91     1.87

Expected life of the options

     5.4 years        5.1 years        5.1 years   

Expected volatility of the underlying stock

     117     121     119

Expected dividend rate

     0     0     0